12:00 AM
May 31, 2010
 |  BC Week In Review  |  Company News  |  Deals

Genaera, Ligand deal

Ligand acquired the milestone and royalty rights to MEDI-528 from Genaera's Genaera Liquidating Trust for $2.8 million. Genaera was eligible for up to $55 million in milestones, plus royalties, from MedImmune Inc....

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >